Lentiviral human BTN3A2 sgRNA gene knockout kit

Lentiviral human BTN3A2 sgRNA gene knockout kit

Catalog Number:
CGKK546300FEN
Mfr. No.:
HKO-611010
Price:
$878
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Kit Components: Lentiviral particles or plasmids for a set of three sgRNAs, and a pair of Indel screening PCR primers

          sgRNA lentiviral particle information
          • Functional titer: 1x10^8 TU/ml
          • Titration method: counting puromycin resistant cell clones
          • Purity: In vivo grade
          • Pseudotype: VSVG
          • Storage buffer: LentiShield™ lentivirus storage buffer
          • Storage: condition -80°C
          • Availability: 3-5 weeks

          sgRNA lentiviral plasmid information
          • Promoter for target sgRNA: U6
          • Mammalian selection: puromycin
          • Promoter for mammalian selection gene: EF1a
          • E.coli selection: Amp
          • Storage condition: -20°C
          • Availability: 1-2 weeks

          Please contact us at for specific academic pricing.

          Target Information

          Target Name
          Human BTN3A2
          About Target
          Gene symbol: BTN3A2
          Synonyms: BT3.2 BTF4 BTN3.2 CD277
          Species: HUMAN
          Gene ID: 11118
          Summary: This gene encodes a member of the immunoglobulin superfamily, which resides in the juxta-telomeric region of the major histocompatability class 1 locus and is clustered with the other family members on chromosome 6. The encoded protein may be involved in the adaptive immune response. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jun 2013].
          NM numbers targeted (Accession number:Exon:CDS Fragment): NM_007047:5:3 NM_001197246:3:3 NM_001197247:5:3 NM_001197248:3:3 NM_001197249:4:2
      • Properties
        • * For Research Use Only.

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.